Costs associated with intravenous chemotherapy administration in patients with small cell lung cancer: A retrospective claims database analysis

Current Medical Research and Opinion

Volumn 24, Issue 4, 2008, Pages 967-974

  Mei, Sheng Duh ^a   Weiner, Jennifer Reynolds ^a   Lefebvre, Patrick ^a   Neary, Maureen ^b   Skarin, Arthur T ^c  

^a ANALYSIS GROUP   (United States)

^b GLAXOSMITHKLINE   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Cost IV chemotherapy; Small cell lung cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IRINOTECAN; TOPOTECAN; VINCRISTINE;

BILLING AND CLAIMS; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; DATA ANALYSIS; DATA BASE; DRUG COST; HUMAN; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; RETROSPECTIVE STUDY;

ADMINISTRATION, ORAL; AGED; ALGORITHMS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARBOPLATIN; CARCINOMA, SMALL CELL; CISPLATIN; COST-BENEFIT ANALYSIS; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FEMALE; HEALTH CARE COSTS; HUMANS; INFUSIONS, INTRAVENOUS; INSURANCE CLAIM REVIEW; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TOPOTECAN; UNITED STATES; VINCRISTINE;

EID: 42549118694     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079908X280464     Document Type: Conference Paper

References (21)

1. American Cancer Society. Small cell lung cancer detailed guide. April 2007. Available at: http://documents.cancer. org/6975.00/6975.00.pdf [last accessed 24 April 24 2007]
2. Cook RM, Miller YE, Bunn PA Jr. Small cell lung cancer: etiology, biology, clinical features, staging and treatment. Curr Probl Cancer 1993;17:69-141
3. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006;24:4539-44
4. American Cancer Society and National Comprehensive Cancer Network. Lung cancer: treatment guidelines for patients. Version III, October 2006. Available at: http://www.cancer.org/downloads/CRI/Lung_Cancer_III.pdf [Last accessed 24 April 2007]
5. Gralla RJ. Quality-of-life considerations in patients with advanced lung cancer: effect of topotecan on symptom palliation and quality of life. Oncologist 2004;9:14-24
6. DeMario MD, Ratain MJ. Oral chemotherapy: rationale and future directions. J Clin Oncol 1998;16:2557-67
7. Navarro RP, Morrow T, Baran R. Pharmacoeconomic and clinical outcomes in oncology using oral chemotherapy. Manag Care Interface 2002;15:55-62
8. Gridelli C, Bareschino MA, Schettino C, et al. Erlotinib in non-small cell lung cancer treatment: current status and future development. Oncologist 2007;12:840-9
9. GSK receives approval for Hycamtin (topotecan) capsules for the treatment of relapsed small cell lung cancer. GlaxoSmithKline press release. 15 October 2007. Available at: http://www.gsk. com/ControllerServlet?appId=4&pageId= 402&newsid=1131 [last accessed 19 December 2007]
10. Doyle JJ, Dezii CM, Sadana A. A pharmacoeconomic evaluation of cisplatin in combination with either etoposide or etoposide phosphate in small cell lung cancer. Semin Oncol 1996;23:51-60
11. Pashko S, Johnson DH. Potential cost savings of oral versus intravenous etoposide in the treatment of small cell lung cancer. Pharmacoeconomics 1992;1:293-7
12. Virnig B, Durham S. Post coverage analysis: use of positron emission tomography (PET) scans: final report. Research Data Assistance Center, Division of Health Services Research and Policy, School of Public Health, University of Minnesota, September 20, 2004. Available at http://www.cms.hhs.gov/ DeterminationProcess/Downloads/PCAPetScan.pdf [Last accessed 9 April 2007]
13. National Comprehensive Cancer Network. NCCN Practice Guidelines in Oncology: Small Cell Lung Cancer. V. 1.2008. 20 August 2007. Available at: http://www.nccn.org/professionals/physician_gls/PDF/sclc.pdf [last accessed 27 December 2007]
14. Cooper GS, Yuan Z, Stange KC, et al. The utility of Medicare claims data for measuring cancer stage. Med Care 1999;37:706-11
15. Cooper GS, Yuan Z, Stange KC, et al. Agreement of Medicare claims and tumor registry data for assessment of cancer-related treatment. Med Care 2000;38:411-21
16. Cooper GS, Virnig B, Klabunde CN, et al. Use of SEER-Medicare for measuring cancer surgery. Med Care 2002;40:IV-43-8
17. Hillner BE, McDonald MK, Desch CE, et al. A comparison of patterns of care of nonsmall cell lung carcinoma patients in a younger and Medigap commercially insured cohort. Cancer 1998;83:1930-7
18. Lamont EB, Herndon JE, Weeks JC, et al. Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants. J Natl Cancer Inst 2005;97:1080-3
19. Thomas SK, Brooks SE, Mullins CD, et al. Use of ICD-9 as a proxy for stage of disease in lung cancer. Pharmacoepidemiol Drug Saf 2002;11:709-13
20. Kim P. Cost of cancer care: the patient perspective. J Clin Oncol 2007;25:228-32
21. Yabroff KR, Davis WW, Lamont EB, et al. Patient time costs associated with cancer care. J Natl Cancer Inst 2007;99:14-23